TRIANA Biomedicines announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating TRI-611, an investigational treatment for ALK-positive non-small cell lung cancer. The study marks an important early milestone in the continued development of new potential treatment options for the ALK-positive community.
Read the full TRIANA Biomedicines press release here:
https://trianabio.com/press-release-031926-1
To learn more about TRI-611, the clinical trial, and patient perspectives on this developing treatment approach, read ALK Positive board member and patient Jeff’s detailed overview here: https://alkpositive.org/blog/tri-611/
